All In Biotech

Free tool

FAERS Monitor: Omlyclo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761399 or its brand name (Omlyclo, Omalizumab-Igec). Reports on generic versions are filed under their own applications.

Reports

89

Serious

88

99% of reports

Hospitalization

13

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urticaria20
  • angioedema16
  • pruritus16
  • dyspnoea15
  • malaise15
  • asthma14
  • product substitution issue13
  • vomiting13
  • cough12
  • headache12
  • pneumonia12
  • wheezing12
  • arthralgia10
  • chest pain10
  • dizziness10

Reports by year received

View as table
YearReports
20191
20221
20255
202682

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,070 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
angioedemaSignal1685.554.91,255
product substitution issueSignal1353.432.3618
wheezingSignal1247.828.3506
asthmaSignal1429.318.1357
urticariaSignal2028.219.2502
chest painSignal1012.87.198
coughSignal1210.16.091
pruritusSignal169.86.3121
pneumoniaSignal128.85.276
malaiseSignal158.15.188
vomitingSignal136.54.057
dyspnoeaSignal156.33.963
arthralgiaSignal105.73.235
dizzinessSignal104.72.627
headacheSignal124.52.730

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.